2021 above, was framed against it
10.1080/08830185.2017.1380200 Int Rev Immunol
"Obesity Drugs: The Next Wave of GLP-1 Competition." September 2024
The formula addresses multiple systems through gut health and botanicals, at a price point that's easier to sustain long-term
Evidence suggests that peptides like Thymosin Alpha1, BPC157, KPV, and Thymosin Beta 4 can modulate immune responses, promote healing, and support gut health
Performance and volatility metrics Performance and volatility metrics (as of 6/30/2026) Morningstar ratings and rankings Morningstar ratings and rankings (as of 6/30/2026) Overall Large Value (Out of 1054 funds) Three Year 46th percentile (472 out of 1054) Five Year 40th percentile (369 out of 991) Ten Year 33rd percentile (253 out of 830) The Overall Morningstar Rating for a fund is derived from a weighted-average of the performance figures associated with its three-, five- and ten-year (if applicable) ratings